Australia Insists Orphan Designations Will Last Only Six Months, Overrides Industry Objections
Executive Summary
Sponsors making drugs for rare diseases in Australia who fail to file for approval within six months of being granted orphan designation will see their designation disappear, the Therapeutic Goods Administration has decided. The new procedure will be problematic for orphan drug sponsors and might even make it more difficult for them to use the new expedited pathways the agency is planning to introduce for innovative drugs.
You may also be interested in...
India Pushing Ahead With Rare Disease Policy Plan
India appears to be on course to developing a national rare disease policy, with the adoption of a specific definition for rare diseases and the initiation of a rare disease registry in the country.
Requests For EMA PRIME Designation Fall But Improvements Are On The Way
While the European Medicines Agency and industry speculate as to why 2022 saw far fewer applications for a place on the priority medicines scheme for drugs for unmet medical needs, they are enthusiastic about improvements to the initiative that are set to be trialed soon.
Improved Commercial Deal Helps PTC Win English Funding For Duchenne Drug
PTC Therapeutics has managed to convince England’s health technology assessment institute to reverse its recommendation against routine commissioning for Translarna.